Medicxi Research
Investment Thesis
Medicxi is a European life sciences venture capital firm built around a single, distinctive idea: the "asset-centric" investment model, coined by co-founder Francesco De Rubertis. Rather than funding broad drug-discovery "platforms" with large teams, infrastructure, and diversified pipelines, Medicxi backs single-asset or dual-asset companies built around one or two experimental medicines with a clear, near-term value-inflection path (typically a proof-of-concept clinical readout). The firm argues that platform biotechs dilute capital and management attention across many programs, while an asset-centric structure lets a small, highly experienced team of scientist-investors drive one program to a data readout as capital-efficiently as possible, leaving portfolio-level diversification to the fund rather than the company. Medicxi frequently seeds, incubates, and even co-founds these companies itself, in-licensing or spinning out single assets from pharma and academia and building a lean management structure (often shared operating/finance functions) around them.
Stage Focus
Medicxi invests across the full biotech lifecycle "from concept to clinic," from company creation/seed through Series A, B, and later growth and pre-IPO rounds, and continues to support companies through IPOs and strategic exits. It is unusually willing to be the first check into a newly created single-asset company (frequently founding the company itself around an in-licensed program) as well as backing later, more capital-intensive clinical-stage rounds.
Check Size
No fixed check-size range is publicly disclosed. Individual disclosed rounds range widely, e.g. a $40M investment in D3 Bio (2024) up to hundreds of millions across a company's lifetime as it advances through clinical stages, consistent with a fund that both seeds new companies and leads large follow-on rounds.
Lead Tendency
Medicxi frequently leads or co-founds/creates the companies it backs, reflecting the asset-centric model where the firm is often the originating investor for a newly spun-out program.
Recent Activity
Medicxi closed its sixth fund, Medicxi V, at €500M (~$581M) in November 2025 — its largest fund to date, bringing total capital raised across six funds over ten years to more than €2.0 billion. Since its previous 2023 fundraise, the firm says it created 16 new companies, delivered 20+ positive clinical data readouts, and realized over $1 billion across its portfolio through exits. The firm continues to actively deploy from Fund V and manages the legacy Index Ventures life sciences portfolio. Recent portfolio exits include Vicebio (acquired by Sanofi for up to $1.6B, announced July 2025), RAPT Therapeutics (acquisition agreed by GSK for ~$1.9-2.2B, announced January 2026), and Centessa Pharmaceuticals (acquired by Eli Lilly for ~$7.8B, agreement March 2026, completed June 2026).
Portfolio Highlights
Medicxi's ~80-company portfolio spans two decades of biotech investing (including the legacy Index Ventures life sciences book) and includes numerous strategic exits to major pharma: Centessa Pharmaceuticals (Eli Lilly), Cellzome (GSK), Micromet (Amgen), Oncoethix (Merck KGaA), PanGenetics (Abbott), Parallele Bioscience (Affymetrix), Funxional Therapeutics (Boehringer Ingelheim), Profibrix (The Medicines Company), MiroBio (Gilead Sciences, ~$405M, 2022), Versanis Bio (Eli Lilly, ~$1.9B, 2023), and Vicebio (Sanofi, up to $1.6B, 2025). Publicly traded portfolio companies include Novocure, Genmab, Merus, Molecular Partners, Evotec, RAPT Therapeutics, Phathom Pharmaceuticals, Aura Biosciences, New Amsterdam Pharma, and Abivax. Active private portfolio companies span oncology, immunology, cardiometabolic disease, infectious disease/vaccines, neuroscience, and rare disease, including D3 Bio, Ethyreal Bio, Altesa BioSciences, Alys Pharmaceuticals, and Curevo.
Team
- Francesco De Rubertis — Co-founder & Partner. Developed the asset-centric investing model; previously a Partner at Index Ventures for 19 years, where he launched its life sciences practice; PhD in Molecular Biology (Geneva), postdoc at MIT's Whitehead Institute.
- Giovanni Mariggi — Co-founder & Partner. Previously Principal at Index Ventures; led investments in Vicebio (Sanofi), Aura Biosciences (Nasdaq: AURA), New Amsterdam Pharma (Nasdaq: NAMS), Curevo, and Abivax (Euronext: ABVX); PhD in Biochemistry & Molecular Biology (UCL).
- Nick Williams — Partner (joined 2018). Led investments in RAPT Therapeutics (GSK), MiroBio (Gilead), Versanis Bio (Eli Lilly), and Phathom Pharmaceuticals; clinically trained pharmacist with a PhD in drug delivery (Cardiff).
- Shyam Masrani — Partner (promoted November 2025). Led investments in Merus and ProfoundBio; serves on the boards of Acera Therapeutics, T-Cypher Bio, and Petalion Therapeutics.
- Broader investment team includes Richard Lee, Victoria Taylor, David Grainger, Moncef Slaoui, Trevor Baglin, Michèle Ollier, Giuseppe Zocco, and others, alongside a dedicated operations team.
Decision Process
Partnership-style decision-making among a small group of scientist-investor partners; the firm's small, high-conviction team structure mirrors the lean, single-asset companies it backs.
Founder Preferences
Medicxi favors scientific entrepreneurs and management teams focused tightly on a single product vision (rather than platform builders), and it is comfortable building the management team and company structure itself around an in-licensed or spun-out asset.
Geographic Focus
European life sciences investor headquartered in London and Geneva, with a portfolio spanning Europe, the US, and increasingly China/Asia (e.g., D3 Bio).